Clinical Trials Directory

Trials / Unknown

UnknownNCT05148182

Metabolomics Characterization of Biomarkers of ASCVD and Prediction Model

Status
Unknown
Phase
Study type
Observational
Enrollment
1,869 (estimated)
Sponsor
Shanghai 10th People's Hospital · Academic / Other
Sex
All
Age
18 Years – 90 Years
Healthy volunteers
Accepted

Summary

1. Describe the risk factors and metabonomics characteristics of atherosclerotic cardiovascular disease in Chinese patients. 2. Establish accurate prediction model of atherosclerotic heart disease.

Detailed description

According to the Chinese cardiovascular disease report released in 2017, cardiovascular disease death is the leading cause of death of urban and rural residents, so cardiovascular disease risk assessment is particularly important. The development of cardiovascular risk assessment model was dated from Framingham Heart Study which first proposed the concept of risk factors, and then adjusted the model several times. In 2016, the China-PAR evaluated the cardiovascular disease risk of Chinese population. However, the application of metabolomics in coronary heart disease is a rapidly developing field and also a new field . Therefore, the aim of this study was to 1.Describe the risk factors of atherosclerotic cardiovascular disease and the characteristics of metabolomics in Chinese population. 2\. Establish an accurate prediction model of atherosclerotic heart disease. Research plan: 1. 1869 risk-stratified people were recruited. 2. Plasma samples were collected incluing disease status and other potential influencing factors. 3. Through the high-throughput detection of body metabolites, combined with multivariate statistical analysis, the metabolic markers with significant difference in different risk levels were screened for risk prediction. 4. All recruited people underwent coronary angiography. 5. The distribution of age and gender in each group should be matched and balanced as far as possible.

Conditions

Timeline

Start date
2021-12-15
Primary completion
2024-12-15
Completion
2024-12-15
First posted
2021-12-08
Last updated
2021-12-08

Locations

2 sites across 1 country: China

Source: ClinicalTrials.gov record NCT05148182. Inclusion in this directory is not an endorsement.